home All News open_in_new Full Article

European committee says Lilly Alzheimer’s drug shouldn’t get marketing approval

A European regulatory committee rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially dangerous risks of brain bleeding and swelling. The European Medicines Agency committee said the benefits of the new drug, Kisunla, did not outweigh the risks, and it recommended refusing marketing authorization for it. The agency’s Committee for Medicinal Products for Human Use […]


today 7 d. ago attach_file Economics

attach_file Economics
attach_file Other
attach_file Culture
attach_file Politics
attach_file Other
attach_file Economics
attach_file Economics
attach_file Economics
attach_file Events
attach_file Economics
attach_file Economics
attach_file Other
attach_file Other
attach_file Economics
attach_file Other
attach_file Economics
attach_file Other
attach_file Economics
attach_file Economics
attach_file Economics


ID: 715513255
Add Watch Country

arrow_drop_down